India's drug regulator CDSCO has recalled three cough syrups and halted their production after the WHO raised concerns about potential contamination and links to child deaths. The WHO is investigating reports of pediatric illnesses and deaths in India potentially linked to contaminated syrups.
A strong performance in the July-September quarter of 2025-26 (FY26) and expectations of growth from launches and acquisition-led synergies led to a 6.65 per cent jump in the share price of Torrent Pharmaceuticals.
'Earnings growth will be the main driver of India's market in 2026, with profits expected to rise 9% to 10% in H2 FY26 and accelerate to 12% to 15% in FY27.'
Sun Pharmaceutical Industries on Wednesday posted a 2.56 per cent increase in its consolidated net profit to Rs 3,118 crore for the second quarter ended September 30, aided by robust sales in India and emerging markets. The Mumbai-based drug major reported a net profit of Rs 3,040 crore for the July-September quarter of the last fiscal.
Sandwiched between a Hero MotoCorp showroom and a shop that hires out cooking utensils is a small, dingy building that's been locked up. The non-descript two-room building is a manufacturing unit of Sresan Pharmaceuticals, the pharma company made its Coldriff cough syrup that has allegedly killed 25 children in Madhya Pradesh.
Among the Sensex firms, Bharat Electronics Ltd, Mahindra & Mahindra, Adani Ports, HCL Technologies, Eternal, Infosys, Bharti Airtel, Sun Pharmaceuticals, Larsen & Toubro, Hindustan Unilever and UltraTech Cement were the gainers. Bajaj Finance, Tata Motors Passenger Vehicles, Kotak Mahindra Bank, PowerGrid and Tata Steel were among the laggards.
India's merchandise trade deficit widened to a record $41.68 billion in October, as gold imports trebled and outbound shipments registered their sharpest contraction in 14 months, according to data released by the commerce department.
'Don't look at Russia only as a place to earn quickly and then leave.' 'Try to build experience in serious companies, skills and certifications that will serve you anywhere in the world.'
United States President Donald Trump on Friday announced that his administration will impose a 100 per cent tariff on branded and patented pharmaceutical products beginning October 1, 2025, unless the manufacturing companies are building production facilities in the US.
Trump said California has been particularly "hard hit" because of this, blaming democrat Gavin Newsom, the Governor of California, for this loss, calling him "weak and incompetent."
The Central Drugs Standard Control Organisation (CDSCO) has initiated a nationwide campaign to test, inspect, and audit cough syrup manufacturers following concerns about contaminated products and child deaths. The initiative aims to ensure adherence to safety standards and regulatory compliance.
In the aftermath of the Red Fort blast, families identified their loved ones through tattoos and clothing. The blast claimed at least 12 lives and injured many others.
Police have arrested a doctor for alleged negligence and registered a case against the manufacturer of a 'toxic' cough syrup after the death of 14 children in Chhindwara due to suspected renal failure, officials said on Sunday.
The Central Drugs Standard Control Organisation (CDSCO) will conduct testing, inspection and auditing of cough syrup manufacturers.
Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company, which had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, said its managing director & global CEO, Umang Vohra, has decided not to seek re-appointment upon completion of his current term on March 31, 2026, Cipla Ltd said in a regulatory filing.
The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.
In a major development in the toxic syrup tragedy that killed 23 children in Madhya Pradesh, S Ranganathan, director of the Tamil Nadu-based Sresan Pharmaceuticals, has been arrested and remanded to 10 days' police custody.
After a year of modest returns, equity investors may anticipate gains of 10-15 per cent in Samvat 2082, which began on October 21. Although valuations have moderated from their peaks a year earlier, they remain above long-term averages, potentially limiting sharp upsides.
The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts. Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), HSBC Global Investment Research said in a report.
The WHO will take a call on issuing a 'Global Medical Products Alert' on the cough syrup, Coldrif, after receiving an official confirmation from authorities here. The agency issues such alerts for substandard and contaminated medicines.
Amid controversy over USPresident Donald Trump's comments linking the use of Tylenol and other related paracetamol products by pregnant women to autism in children, experts and industry executives say that since India's export of the drug to the US is less, it will hardly affect the country's pharma exports to America.
The Indian Medical Association (IMA) has defended a doctor arrested in connection with cough syrup deaths in Madhya Pradesh, attributing the incident to failures in the drugs regulatory system.
The World Health Organisation (WHO) has issued an alert against three "substandard" oral cough syrups identified in India and urged national regulatory authorities worldwide to immediately notify it if these are detected in their country.
Madhya Pradesh Deputy Chief Minister Rajendra Shukla confirmed that 20 children have died after consuming contaminated cough syrup. An investigation is underway, and action has been taken against the manufacturer, doctor, and FDA officials.
'They are a poor fit for anyone with near-term goals, low volatility tolerance, or a need for steady income or liquidity.' 'First-time investors should typically avoid them.'
The Madhya Pradesh government will cover the full cost of treatment for children suffering from kidney infections after consuming a contaminated cough syrup in Chhindwara and Betul districts. This decision follows the deaths of fourteen children in Chhindwara due to suspected renal failure linked to the 'toxic' Coldrif cough syrup.
A special investigation team (SIT) has been formed in Madhya Pradesh to investigate the deaths of 14 children in Chhindwara, suspected to be linked to a toxic cough syrup. The investigation includes arrests, exhumations, and a ban on the implicated cough syrup.
The death toll from contaminated cough syrup in Madhya Pradesh has risen to 22, with two more children succumbing to kidney infections. An investigation is underway, and arrests have been made.
The Maharashtra Food and Drug Administration (FDA) on Monday appealed to the people to immediately stop the sale or use of a specific batch of Coldrif syrup, following child deaths in Madhya Pradesh and Rajasthan allegedly linked to the medicine.
Tamil Nadu Government will take criminal action against a drug manufacturer, whose cough syrup has been banned in the wake of children's deaths in Madhya Pradesh, state minister Ma Subramanian said here on Wednesday.
As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.
Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.
From serial killers to genies, interesting content ready to entertain you and satisfy your inner cinephile.
Tata Sons, now debt-free, has asked the RBI to drop its 'upper-layer NBFC' tag and allow it to stay private.
The government's move to cut GST on medicines and medical devices while exempting lifesaving drugs from the levy is a bold step that will bring direct relief to patients and families while significantly reducing financial strain on them, pharmaceuticals and healthcare industry players said on Thursday.
Health ministry advisory urges rational use of cough syrups in children after 11 deaths in Madhya Pradesh and Rajasthan.
Credit quality of Indian corporate is expected to be stable in the second half of the current financial year (H2FY26), supported by easing monetary cycle, and declining inflation, coupled with income-tax relief and rationalisation of the goods and service tax (GST) rates, among others.
A man in Delhi was critically injured after his wife allegedly poured boiling oil on him while he was sleeping. The incident occurred in their Madangir home, and the victim is currently in the ICU.
'The outlook for the next Samvat is more constructive, as many of the earlier drags are gradually becoming supports.'
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances